Clinical and experimental evidence suggest that estrogen manipulates
intracellular iron metabolism and that elevated levels of estrogen associate
with increased systemic iron availability. This has been attributed to the
ability of estrogen to suppress hepcidin synthesis, maintain ferroportin
integrity and enhance iron release from iron-absorbing duodenal enterocytes
and iron-storing macrophages and hepatocytes. These observations speak of a
potential “estrogen-iron” axis that manipulates iron
metabolism in response to hematologic (erythropoiesis) and non-hematologic
(uterine growth, pregnancy, lactation) needs for iron. Such an axis could
contribute to minimizing iron deficiency in premenopausal women and iron
overload in postmenopausal women. It could also exacerbate iron overload and
related clinical consequences including cancer, osteoporosis, cardiovascular
complications and neurodegenerative symptoms, especially in postmenopausal
women on hormonal replacement therapy. Understanding the role of estrogen in
iron metabolism may shed some light on the pleotropic, but often
paradoxical, roles of estrogen in human health and disease.